Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

COVID-19 and colchicine - Can we weather the storm?

*Corresponding Author:

Copyright: © 2020  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 
To read the full article Peer-reviewed Article PDF image

Abstract

We read with interest the study published by Cavalli et al. which showed that blocking interleukin-1 (IL-1) with high-dose of anakinra was safe and resulted in clinical improvement in 72% of patients with ARDS managed with non-invasive ventilation outside the intensive care unit [1]. Anakinra is a recombinant human IL-1 receptor antagonist that binds to the IL-1 receptor and block signal transduction. It is approved by FDA for rheumatoid arthritis and autoinflammatory syndromes treatment.

Keywords

Top